Tralyte Health is creating a portable device that enables patients with hypoparathyroidism to measure calcium levels at home, providing rapid, clinically relevant electrolyte data without waiting for lab results. The system targets the need for same‑day treatment adjustments and plans to expand to monitor additional electrolytes as the platform matures.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with hypoparathyroidism experience rapid fluctuations in blood calcium that can lead to serious symptoms, yet current monitoring relies on periodic laboratory draws and delayed reporting, preventing timely treatment adjustments.
Solution
Tralyte Health is developing a portable, point‑of‑need device that measures calcium levels from a small blood sample at home. The system uses a proprietary optical sensing method to generate a signal proportional to calcium concentration in plasma, enabling accurate results without a central lab. Results can be viewed instantly on the device or synced to a companion smartphone app for longitudinal tracking. By delivering same‑day biochemical insight, the solution allows patients and clinicians to make more responsive dosing decisions, reducing the risk of complications associated with calcium instability. The platform is designed to expand to additional electrolytes, creating a broader at‑home metabolic monitoring toolkit.
Target Audience
Primary users are individuals with hypoparathyroidism who require frequent calcium monitoring, as well as endocrinologists and primary‑care providers managing electrolyte disorders.
Features
- Optical sensing technology optimized for calcium detection in a compact, user‑friendly cartridge
- Minimal sample requirement (finger‑stick blood) with no need for venous draw
- Immediate on‑device readout and optional Bluetooth sync to a smartphone app for trend visualization
- Designed for point‑of‑need use, supporting home monitoring and rapid clinical decision‑making
- Scalable architecture planned to incorporate other electrolytes (e.g., potassium, sodium, lithium) in future iterations